

Isolda Casanova Rigat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2967765/publications.pdf>

Version: 2024-02-01

58
papers

1,674
citations

257101

24
h-index

315357

38
g-index

58
all docs

58
docs citations

58
times ranked

2516
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4+ head and neck squamous cell carcinoma tumors. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2578-2591.	5.7	15
2	A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. <i>Biomaterials</i> , 2022, 280, 121258.	5.7	12
3	Time-Prolonged Release of Tumor-Targeted Proteinâ€“MMAE Nanoconjugates from Implantable Hybrid Materials. <i>Pharmaceutics</i> , 2022, 14, 192.	2.0	8
4	CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 49.	3.5	24
5	Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. <i>Journal of Controlled Release</i> , 2022, 343, 277-287.	4.8	7
6	A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model. <i>Pharmaceutics</i> , 2022, 14, 887.	2.0	5
7	A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112940.	2.5	4
8	GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases. <i>Drug Delivery</i> , 2022, 29, 1384-1397.	2.5	16
9	Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease. <i>Biomedicines</i> , 2022, 10, 1680.	1.4	6
10	Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles. <i>Acta Biomaterialia</i> , 2021, 119, 312-322.	4.1	14
11	Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1869-1888.	3.3	16
12	Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4+ Cancers. <i>Cancers</i> , 2021, 13, 2929.	1.7	11
13	Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. <i>Journal of Controlled Release</i> , 2021, 335, 117-129.	4.8	11
14	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. <i>Haematologica</i> , 2020, 105, 741-753.	1.7	36
15	Engineering Secretory Amyloids for Remote and Highly Selective Destruction of Metastatic Foci. <i>Advanced Materials</i> , 2020, 32, e1907348.	11.1	40
16	Artificial Inclusion Bodies for Clinical Development. <i>Advanced Science</i> , 2020, 7, 1902420.	5.6	36
17	Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles. <i>Pharmaceutics</i> , 2020, 12, 1004.	2.0	25
18	An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. <i>Journal of Hematology and Oncology</i> , 2020, 13, 36.	6.9	39

#	ARTICLE	IF	CITATIONS
19	Selective delivery of T22-PE24-H6 to CXCR4 ⁺ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model. <i>Theranostics</i> , 2020, 10, 5169-5180.	4.6	22
20	Effect of serpinE1 overexpression on the primary tumor and lymph node, and lung metastases in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 429-439.	0.9	28
21	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2019, 104, 778-788.	1.7	17
22	Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4 ⁺ colorectal cancer. <i>Acta Biomaterialia</i> , 2019, 99, 426-432.	4.1	11
23	Protein-driven nanomedicines in oncotherapy. <i>Current Opinion in Pharmacology</i> , 2019, 47, 1-7.	1.7	21
24	Efficient bioactive oligonucleotide-protein conjugation for cell-targeted cancer therapy. <i>ChemistryOpen</i> , 2019, 8, 382-387.	0.9	7
25	The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial-like head and neck carcinoma subtypes. <i>Head and Neck</i> , 2019, 41, 1830-1845.	0.9	9
26	Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs. <i>Journal of Controlled Release</i> , 2018, 274, 81-92.	4.8	55
27	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 436.	1.7	8
28	Selective depletion of metastatic stem cells as therapy for human colorectal cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	64
29	Selective CXCR4 ⁺ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin. <i>Small</i> , 2018, 14, e1800665.	5.2	40
30	CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4 ⁺ patients with good prognosis. <i>PLoS ONE</i> , 2018, 13, e0198789.	1.1	10
31	Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells. <i>Scientific Reports</i> , 2017, 7, 13946.	1.6	34
32	<i>NEDD9</i> , an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients. <i>Oncotarget</i> , 2017, 8, 76003-76014.	0.8	5
33	uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. <i>Oncotarget</i> , 2016, 7, 57351-57366.	0.8	120
34	Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4 ⁺ colorectal cancer models. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1987-1996.	1.7	34
35	CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1392-403.	0.9	16
36	Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Target-Preferential Release of Doxorubicin in CXCR4-Expressing Lymphoma Cells. <i>Advanced Functional Materials</i> , 2015, 25, 687-695.	7.8	54

#	ARTICLE	IF	CITATIONS
37	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. <i>FASEB Journal</i> , 2015, 29, 464-476.	0.2	43
38	<scp>CXCR4</scp> expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. <i>Journal of Pathology</i> , 2015, 235, 445-455.	2.1	71
39	Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. <i>Oncotarget</i> , 2015, 6, 29016-29033.	0.8	62
40	Focal adhesion protein expression in human diffuse large B cell lymphoma. <i>Histopathology</i> , 2014, 65, 119-131.	1.6	9
41	Subcutaneous preconditioning increases invasion and metastatic dissemination in colorectal cancer models. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 387-96.	1.2	8
42	<i>In Vivo</i> Architectonic Stability of Fully <i>de Novo</i> Designed Protein-Only Nanoparticles. <i>ACS Nano</i> , 2014, 8, 4166-4176.	7.3	89
43	A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement. <i>Haematologica</i> , 2013, 98, 1242-1249.	1.7	3
44	High RAB 25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2013, 2, 950-963.	1.3	13
45	Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma. <i>Carcinogenesis</i> , 2012, 33, 1707-1716.	1.3	31
46	Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles. <i>International Journal of Nanomedicine</i> , 2012, 7, 4533.	3.3	61
47	Subcutaneous passage increases cell aggressiveness in a xenograft model of diffuse large B cell lymphoma. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 339-347.	1.7	5
48	A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 4411-4420.	0.6	18
49	Site-Dependent E-Cadherin Cleavage and Nuclear Translocation in a Metastatic Colorectal Cancer Model. <i>American Journal of Pathology</i> , 2010, 177, 2067-2079.	1.9	35
50	A celecoxib derivative inhibits focal adhesion signaling and induces caspase-dependent apoptosis in human acute myeloid leukemia cells. <i>International Journal of Cancer</i> , 2008, 123, 217-226.	2.3	20
51	<i>Ku</i>70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer. <i>International Journal of Cancer</i> , 2008, 123, 1068-1079.	2.3	38
52	Bobel-24 and Derivatives Induce Caspase-Independent Death in Pancreatic Cancer Regardless of Apoptotic Resistance. <i>Cancer Research</i> , 2008, 68, 6313-6323.	0.4	16
53	Mouse models in oncogenesis and cancer therapy. <i>Clinical and Translational Oncology</i> , 2006, 8, 318-329.	1.2	116
54	Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas. <i>International Journal of Cancer</i> , 2006, 118, 2381-2389.	2.3	34

#	ARTICLE	IF	CITATIONS
55	K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. <i>Carcinogenesis</i> , 2006, 27, 2190-2200.	1.3	58
56	Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by Myc. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1166-1175.	1.9	11
57	Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. <i>FASEB Journal</i> , 2002, 16, 1642-1644.	0.2	34
58	Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a new metastatic site in a human pancreatic tumor xenograft model. <i>FASEB Journal</i> , 2002, 16, 975-982.	0.2	19